Dual Inhibition of Endoplasmic Reticulum Stress and Oxidation Stress Manipulates the Polarization of Macrophages under Hypoxia to Sensitize Immunotherapy

Abstract

M2-tumor associated macrophages (TAMs) play an important role in tumor genesis, progression, and metastasis, and repolarizing M2-TAMs to immune-promoting M1 type is increasingly recognized as a promising strategy against the clinically intractable carcinomas. It is observed that M2 macrophages have a high tropism to the tumor hypoxic area, with their endoplasmic reticulum (ER) stress-associated IRE1-XBP1 pathway activated to inhibit cell glycolysis, promote oxidative phosphorylation (OXPHOS), and facilitate intracellular lipid accumulation, which in turn shapes the typical phenotypes of M2-TAMs, suggesting that manipulating the ER stress response of M2-TAMs might stand as a breakthrough for antitumor therapy. However, current attempts to repolarize M2 cells remain limited and are greatly challenged by the hypoxic nature of tumors. Also, the high level of reactive oxygen species (ROS) in the tumor microenvironment (TME) is favorable for the polarization of M2-TAMs. Here, we encapsulated KIRA6, an inhibitor of the IRE1-XBP1 pathway, into a reductive nanoemulsion containing α-tocopherol. Our α-T-K had dual inhibitory effects on the ER stress and oxidative stress. Both in vitro and in vivo experiments suggested that α-T-K effectively reprogrammed M2 macrophages even under hypoxia, achieved by increasing glycolysis and suppressing fatty acid oxidation (FAO). In addition, our data revealed that α-T-K not only delayed tumor growth but elevated the curative effect of PD-1 antibody. Our research demonstrated that simultaneous inhibition of ER stress and oxidative stress could effectively repolarize M2-TAMs under hypoxia, which not only filled the current gap in regulating the biological repolarization of macrophages under hypoxia but provided a meaningful reference for the clinical immunotherapy of sensitized anti-PD-1.

Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma?

“…Furthermore, a recent study has shown that ablation of PERK promotes antitumor T-cell responses by inducing paraptosis and type I interferon, suggesting that antitumor immunity could be modulated by the ERSR [ 164 ]. Inhibition of the IRE1-XBP1 pathway effectively repolarizes M2-tumor associated macrophages, and elevates the antitumor efficacy of PD-1 antibodies [ 165 ], highlighting the favorable dual impact on both tumoral and intratumoral immune cells by targeting the ERSR. Collectively, increasing evidence has implicated the potential of targeting ERSR-associated proteins to improve the efficacy of cancer immunotherapy.…”

Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response

“…The hostile milieu for immune cells formed by tumors is one of the most critical reasons for the limited response of tumor immunotherapies, such as immune checkpoint inhibitors (ICIs). − The TME is immunosuppressive with distinctive features, such as nutrient deficiency, hypoxia, weak acid, high redox, and immunosuppressive factors. , Therefore, reshaping the “self-interested” environment to an “immune-friendly” one is crucial for effective immunotherapy, which has been confirmed by many research reports. − It is extensively reported that the weak acidification of the TME can provide a selective advantage for tumor growth and immunity suppression (Figure ), and its neutralization is beneficial to improve the response of the ICB. ,, …”

A Clinically-Achievable Injectable and Sprayable in Situ Lyotropic Liquid Crystalline Platform in Treating Hormone-Sensitive and Castration-Resistant Prostate Cancer

“…Phosphatidylcholine serves as the most widely spread elements in cells membranes and α-tocopherol acts as an essential fat-soluble vitamin, both of which have excellent biocompatibility. 41 We changed the ratios of PC and α-T in an effort to investigate crystalline type transitions, detailed characterization, syringeability, sprayability, viscoelastic properties, releasing behaviors, as well as the biocompatibility. Finally, we chose PC/α-T= 4:4 in H II phase as the final formulation for subsequent studies owing to its great biosafety as well as a behavioral characteristic of simultaneous releasing hydrophilic and hydrophobic drugs.…”